Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Sponsor: Guangzhou Medical University
Summary
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
Official title: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2024-06-30
Completion Date
2026-07-30
Last Updated
2025-09-29
Healthy Volunteers
No
Conditions
Interventions
Toripalimab, pemetrexed
Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
Locations (1)
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, China